<?xml version="1.0" encoding="UTF-8"?><rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>Clinical Workflow &amp; Documentation Archives - MoleMax Systems</title>
	<atom:link href="https://molemaxsystems.com/category/clinical-workflow-documentation/feed/" rel="self" type="application/rss+xml" />
	<link>https://molemaxsystems.com/category/clinical-workflow-documentation/</link>
	<description>Provide the best skin imaging device</description>
	<lastBuildDate>Thu, 06 Aug 2026 07:09:28 +0000</lastBuildDate>
	<language>en-AU</language>
	<sy:updatePeriod>
	hourly	</sy:updatePeriod>
	<sy:updateFrequency>
	1	</sy:updateFrequency>
	

<image>
	<url>https://molemaxsystems.com/wp-content/uploads/2020/10/favicon.png</url>
	<title>Clinical Workflow &amp; Documentation Archives - MoleMax Systems</title>
	<link>https://molemaxsystems.com/category/clinical-workflow-documentation/</link>
	<width>32</width>
	<height>32</height>
</image> 
	<item>
		<title>Global Skin Cancer Burden From 1990 to 2023 and Projection to 2050</title>
		<link>https://molemaxsystems.com/global-skin-cancer-burden-from-1990-to-2023-and-projection-to-2050/</link>
		
		<dc:creator><![CDATA[molemax]]></dc:creator>
		<pubDate>Tue, 09 Jun 2026 00:33:36 +0000</pubDate>
				<category><![CDATA[Clinical Workflow & Documentation]]></category>
		<category><![CDATA[dermatology research]]></category>
		<category><![CDATA[skin cancer]]></category>
		<guid isPermaLink="false">https://molemaxsystems.com/?p=9963</guid>

					<description><![CDATA[<p>Malignant skin cancers impose an escalating and heterogeneous health burden worldwide.</p>
<p>The post <a href="https://molemaxsystems.com/global-skin-cancer-burden-from-1990-to-2023-and-projection-to-2050/">Global Skin Cancer Burden From 1990 to 2023 and Projection to 2050</a> appeared first on <a href="https://molemaxsystems.com">MoleMax Systems</a>.</p>
]]></description>
										<content:encoded><![CDATA[
		<div id="fws_6abf2e870a9b2"  data-column-margin="default" data-midnight="dark"  class="wpb_row vc_row-fluid vc_row top-level"  style="padding-top: 0px; padding-bottom: 0px; "><div class="row-bg-wrap" data-bg-animation="none" data-bg-animation-delay="" data-bg-overlay="false"><div class="inner-wrap row-bg-layer" ><div class="row-bg viewport-desktop"  style=""></div></div></div><div class="row_col_wrap_12 col span_12 dark left">
	<div  class="vc_col-sm-12 wpb_column column_container vc_column_container col no-extra-padding inherit_tablet inherit_phone "  data-padding-pos="all" data-has-bg-color="false" data-bg-color="" data-bg-opacity="1" data-animation="" data-delay="0" >
		<div class="vc_column-inner" >
			<div class="wpb_wrapper">
				
<div class="wpb_text_column wpb_content_element " >
	<nav role="none"><span class="wi-fullname brand-fg">Youyou Zhou, MD, PhD</span><span class="al-author-delim">; </span><span class="wi-fullname brand-fg">Weiming Zhong, MD, PhD</span><span class="al-author-delim">; </span><span class="wi-fullname brand-fg">Xulei Liu, MBBS; </span>Jianglin Zhang, MD, PhD</nav>
<p>&nbsp;</p>
<p>Malignant skin cancers impose an escalating and heterogeneous health burden worldwide.<sup>1</sup> Using the Global Burden of Disease (GBD) 2023 database,<sup>2</sup> we summarize these cancers’ epidemiology, subgroup patterns, and projections to 2050.</p>
<div class="h3 cb section-type-section ">
<h3 class="heading-text thm-col sb-sc"><strong>Methods</strong></h3>
</div>
<p class="para">We analyzed GBD 2023 estimates (1990-2023) for malignant melanoma, cutaneous squamous cell carcinoma, and basal cell carcinoma. Outcomes included prevalence and disability-adjusted life-years (DALYs; years of life lost due to premature death plus years lived with disability). Subgroup analyses were conducted by sex, age group, and Sociodemographic Index (SDI; range, 0-1), defined as the geometric mean of indices of fertility in those younger than 25 years, education among those aged 15 years and older, and lag-distributed income per capita. Projections to 2050 used a bayesian age-period-cohort (BAPC) model, a bayesian hierarchical framework that jointly estimates age, period, and cohort effects and provides uncertainty intervals. For basal cell carcinoma, we excluded the 2005 to 2009 surveillance-artifact period and fit projections using 2010 to 2023 data. Additional methods are provided in the eMethods in Supplement 1. This study was deemed to be not human participant research by Shenzhen People’s Hospital; therefore, institutional review board approval and informed consent were not required.</p>
<p>To read this article in full <a href="https://jamanetwork.com/journals/jamadermatology/fullarticle/2848888?guestAccessKey=2634ca35-bbf2-434d-972c-06ce8df175f5&amp;utm_medium=email&amp;utm_source=postup_jn&amp;utm_campaign=article_alert-jamadermatology&amp;utm_content=olf-tfl_&amp;utm_term=051326" target="_blank" rel="noopener">please click here</a>.</p>
</div>




			</div> 
		</div>
	</div> 
</div></div>
<div class="molemax-categories-injected"><ul class="molemax-cat-list"><li><a href="https://molemaxsystems.com/blog">ALL</a></li><li><a href="https://molemaxsystems.com/category/clinical-workflow-documentation/">CLINICAL WORKFLOW &AMP; DOCUMENTATION</a></li><li><a href="https://molemaxsystems.com/category/dermoscopy-techniques-clinical-studies/">DERMOSCOPY TECHNIQUES &AMP; CLINICAL STUDIES</a></li><li><a href="https://molemaxsystems.com/category/digital-dermoscopy-skin-imaging/">DIGITAL DERMOSCOPY &AMP; SKIN IMAGING</a></li><li><a href="https://molemaxsystems.com/category/evidence-research/">EVIDENCE &AMP; RESEARCH</a></li><li><a href="https://molemaxsystems.com/category/mole-mapping-lesion-tracking/">MOLE MAPPING &AMP; LESION TRACKING</a></li><li><a href="https://molemaxsystems.com/category/molemax-hd-total-body-mapping/">MOLEMAX HD &AMP; TOTAL BODY MAPPING</a></li><li><a href="https://molemaxsystems.com/category/research-clinical-evidence/">RESEARCH &AMP; CLINICAL EVIDENCE</a></li><li><a href="https://molemaxsystems.com/category/skin-cancer-detection-diagnosis/">SKIN CANCER DETECTION &AMP; DIAGNOSIS</a></li><li><a href="https://molemaxsystems.com/category/skin-cancer-research-evidence/">SKIN CANCER RESEARCH &AMP; EVIDENCE</a></li></ul></div><p>The post <a href="https://molemaxsystems.com/global-skin-cancer-burden-from-1990-to-2023-and-projection-to-2050/">Global Skin Cancer Burden From 1990 to 2023 and Projection to 2050</a> appeared first on <a href="https://molemaxsystems.com">MoleMax Systems</a>.</p>
]]></content:encoded>
					
		
		
			</item>
		<item>
		<title>Get an Online MoleMax Demo!</title>
		<link>https://molemaxsystems.com/mole-max-hd-demo-request/</link>
		
		<dc:creator><![CDATA[Clare Ivers]]></dc:creator>
		<pubDate>Wed, 04 Oct 2023 23:39:15 +0000</pubDate>
				<category><![CDATA[Clinical Workflow & Documentation]]></category>
		<guid isPermaLink="false">https://molemaxsystems.com//?p=5440</guid>

					<description><![CDATA[<p>Book a personalised MoleMax HD demo to explore digital dermoscopy, lesion monitoring and clinical workflow tools with a product specialist.</p>
<p>The post <a href="https://molemaxsystems.com/mole-max-hd-demo-request/">Get an Online MoleMax Demo!</a> appeared first on <a href="https://molemaxsystems.com">MoleMax Systems</a>.</p>
]]></description>
										<content:encoded><![CDATA[
<div class="wp-block-contact-form-7-contact-form-selector">[contact-form-7]</div>
<div class="molemax-categories-injected"><ul class="molemax-cat-list"><li><a href="https://molemaxsystems.com/blog">ALL</a></li><li><a href="https://molemaxsystems.com/category/clinical-workflow-documentation/">CLINICAL WORKFLOW &AMP; DOCUMENTATION</a></li><li><a href="https://molemaxsystems.com/category/dermoscopy-techniques-clinical-studies/">DERMOSCOPY TECHNIQUES &AMP; CLINICAL STUDIES</a></li><li><a href="https://molemaxsystems.com/category/digital-dermoscopy-skin-imaging/">DIGITAL DERMOSCOPY &AMP; SKIN IMAGING</a></li><li><a href="https://molemaxsystems.com/category/evidence-research/">EVIDENCE &AMP; RESEARCH</a></li><li><a href="https://molemaxsystems.com/category/mole-mapping-lesion-tracking/">MOLE MAPPING &AMP; LESION TRACKING</a></li><li><a href="https://molemaxsystems.com/category/molemax-hd-total-body-mapping/">MOLEMAX HD &AMP; TOTAL BODY MAPPING</a></li><li><a href="https://molemaxsystems.com/category/research-clinical-evidence/">RESEARCH &AMP; CLINICAL EVIDENCE</a></li><li><a href="https://molemaxsystems.com/category/skin-cancer-detection-diagnosis/">SKIN CANCER DETECTION &AMP; DIAGNOSIS</a></li><li><a href="https://molemaxsystems.com/category/skin-cancer-research-evidence/">SKIN CANCER RESEARCH &AMP; EVIDENCE</a></li></ul></div><p>The post <a href="https://molemaxsystems.com/mole-max-hd-demo-request/">Get an Online MoleMax Demo!</a> appeared first on <a href="https://molemaxsystems.com">MoleMax Systems</a>.</p>
]]></content:encoded>
					
		
		
			</item>
	</channel>
</rss>
